News
BOIRON : 2020 half-year results
(Data have been the subject to a limited review by the statutory auditors)
The Board of Directors, at its meeting of September 9, 2020, made up the half-year statutory and consolidated financial
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six e-posters highlighting clinical data from the lucitanib and Rubraca® (rucaparib) clinical development programs, as well as preclinical
Albireo Pharma: SD-Jubiläumsrakete liefert +115%
Unsere Jubiläumsrakete Albireo Pharma (WKN: A2DF99) knallte gestern dank positiver Studienergebnisse auf bis zu 49,00 US-Dollar und damit 115% auf unseren Empfehlungskurs von 22,78 US-Dollar – was
Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference
Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Positive Initial Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces first positive data from the Phase
Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramostim
CO.DON AG: Behandlung von Patienten in der Schweiz begonnen
Berlin / Teltow / Leipzig, 07. September 2020 – Das INSELSPITAL Bern, Universitätsspital der Universität Bern hat als erste Schweizer Klinik mit der Behandlung von Patienten mit dem 100 %
CO.DON AG: Treatment of patients starts in Switzerland
Berlin / Teltow / Leipzig, 07 September 2020 – The INSELSPITAL in Bern, Bern’s university hospital, has become the first Swiss clinic to start treating patients with the 100% autologous
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN: FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 2, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
Wells Fargo 2020 Virtual Healthcare
Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Epigenomics: Entscheidung vertagt – US-Krankenversicherung zu spät!
Entscheidung vertagt: Wie Epigenomics (WKN: A11QW5) heute Morgen informiert, hat die staatliche US-Krankenversicherung "Centers for Medicare & Medicaid Services", kurz CMS, noch keinen vorläufigen
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test
EnWave Signs Technology Evaluation and License Option Agreement with Leading European Snack Company
Vancouver, B.C., August 26th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced
EnWave unterzeichnet Technologieevaluierungs- und Lizenzoptionsvertrag mit führendem europäischen Snack-Unternehmen
Vancouver, B.C., 26. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
IMV to Participate at Four Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
EnWave Corporation Refining Development of a Medical Device to Relieve COVID-19 Symptoms
Vancouver, B.C., August 25, 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), announced
EnWave Corporation Verfeinerungsentwicklung eines medizinischen Geräts zur Linderung der COVID-19-Symptome
Vancouver, B.C., 25. August 2020, Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced